Published in J Immunol on September 15, 2003
Valpha24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages. J Clin Invest (2009) 1.78
Interleukin-1 family cytokines as mucosal vaccine adjuvants for induction of protective immunity against influenza virus. J Virol (2010) 1.00
Molecular basis of lipid antigen presentation by CD1d and recognition by natural killer T cells. Immunol Rev (2012) 0.99
Developing understanding of the roles of CD1d-restricted T cell subsets in cancer: reversing tumor-induced defects. Clin Immunol (2011) 0.95
Tobacco exposure by various modes may alter proinflammatory (IL-12) and anti-inflammatory (IL-10) levels and affects the survival of prostate carcinoma patients: an explorative study in North Indian population. Biomed Res Int (2014) 0.93
Development of functional human NK cells in an immunodeficient mouse model with the ability to provide protection against tumor challenge. PLoS One (2009) 0.92
Vitamin A supplementation and retinoic acid treatment in the regulation of antibody responses in vivo. Vitam Horm (2007) 0.91
Activation of anti-tumor immune response and reduction of regulatory T cells with Mycobacterium indicus pranii (MIP) therapy in tumor bearing mice. PLoS One (2011) 0.91
Invariant NKT cells are required for antitumor responses induced by host-versus-graft responses. J Immunol (2010) 0.89
TLR4 and NKT cell synergy in immunotherapy against visceral leishmaniasis. PLoS Pathog (2012) 0.87
Retinoic acid modulates interferon-γ production by hepatic natural killer T cells via phosphatase 2A and the extracellular signal-regulated kinase pathway. J Interferon Cytokine Res (2014) 0.79
A functional polymorphism in the promoter region of interleukin-10 gene increases the risk for spontaneous abortions--a triad study. J Assist Reprod Genet (2015) 0.75
The -607C/A polymorphisms in interleukin-18 gene promoter contributes to cancer risk: evidence from a meta-analysis of 22 case-control studies. PLoS One (2013) 0.75
The -137G/C Polymorphism in Interleukin-18 Gene Promoter Contributes to Chronic Lymphocytic and Chronic Myelogenous Leukemia Risk in Turkish Patients. Turk J Haematol (2014) 0.75
Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells (2005) 3.36
Characterization of the optimal culture conditions for clinical scale production of human mesenchymal stem cells. Stem Cells (2005) 2.53
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Transcoronary transplantation of autologous mesenchymal stem cells and endothelial progenitors into infarcted human myocardium. Catheter Cardiovasc Interv (2005) 2.02
Effects of donor age, gender, and in vitro cellular aging on the phenotypic, functional, and molecular characteristics of mouse bone marrow-derived mesenchymal stem cells. Stem Cells Dev (2011) 1.36
Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy. Cancer Immunol Immunother (2008) 1.27
A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer. Cancer Immunol Immunother (2010) 1.26
A new era in anticancer peptide vaccines. Cancer (2010) 1.18
CD4+CD25+ regulatory T-cell frequency in HER-2/neu (HER)-positive and HER-negative advanced-stage breast cancer patients. Clin Cancer Res (2007) 1.10
CRD-BP/IMP1 expression characterizes cord blood CD34+ stem cells and affects c-myc and IGF-II expression in MCF-7 cancer cells. J Biol Chem (2005) 1.07
Natural killer lymphocytes: biology, development, and function. Cancer Immunol Immunother (2003) 1.06
Vaccination with human HER-2/neu (435-443) CTL peptide induces effective antitumor immunity against HER-2/neu-expressing tumor cells in vivo. Cancer Res (2006) 1.05
NK cell adoptive transfer combined with Ontak-mediated regulatory T cell elimination induces effective adaptive antitumor immune responses. J Immunol (2011) 1.03
Immunogenic HER-2/neu peptides as tumor vaccines. Cancer Immunol Immunother (2005) 1.03
A novel myeloid-like NK cell progenitor in human umbilical cord blood. Blood (2002) 1.02
Cell culture medium composition and translational adult bone marrow-derived stem cell research. Stem Cells (2006) 1.02
HER-2/neu as a target for cancer vaccines. Immunotherapy (2010) 1.02
Immune properties of mesenchymal stem cells. Methods Mol Biol (2007) 1.01
Th1 and Th2 serum cytokine profiles characterize patients with Hashimoto's thyroiditis (Th1) and Graves' disease (Th2). Neuroimmunomodulation (2004) 0.97
Electrophysiological effects of intracoronary transplantation of autologous mesenchymal and endothelial progenitor cells. Europace (2007) 0.94
Immunobiology of HER-2/neu oncoprotein and its potential application in cancer immunotherapy. Cancer Immunol Immunother (2003) 0.93
A potential role for hydrocortisone in the positive regulation of IL-15-activated NK-cell proliferation and survival. Blood (2005) 0.92
Results from a phase I clinical study of the novel Ii-Key/HER-2/neu(776-790) hybrid peptide vaccine in patients with prostate cancer. Clin Cancer Res (2010) 0.90
HER-2/neu-derived peptide 884-899 is expressed by human breast, colorectal and pancreatic adenocarcinomas and is recognized by in-vitro-induced specific CD4(+) T cell clones. Cancer Immunol Immunother (2001) 0.89
Peptide vaccination breaks tolerance to HER-2/neu by generating vaccine-specific FasL(+) CD4(+) T cells: first evidence for intratumor apoptotic regulatory T cells. Cancer Res (2010) 0.89
Effect of IL-21 on NK cells derived from different umbilical cord blood populations. Int Immunol (2005) 0.88
Effect of the simultaneous administration of glucocorticoids and IL-15 on human NK cell phenotype, proliferation and function. Cancer Immunol Immunother (2011) 0.88
New insights into the role of NK cells in cancer immunotherapy. Oncoimmunology (2012) 0.87
Increased frequency of CD4+ cells expressing CD161 in cancer patients. Clin Cancer Res (2006) 0.87
AE37: a novel T-cell-eliciting vaccine for breast cancer. Expert Opin Biol Ther (2011) 0.86
Cancer immunotherapy. Crit Rev Clin Lab Sci (2009) 0.85
HER-2/neu-derived peptide epitopes are also recognized by cytotoxic CD3(+)CD56(+) (natural killer T) lymphocytes. Int J Cancer (2002) 0.84
Ii-Key/HER-2/neu(776-790) hybrid peptides induce more effective immunological responses over the native peptide in lymphocyte cultures from patients with HER-2/neu+ tumors. Cancer Immunol Immunother (2006) 0.84
Gamma-irradiation induces HER-2/neu overexpression in breast cancer cell lines and sensitivity to treatment with trastuzumab. Int J Radiat Biol (2013) 0.83
Induction of potent CD4+ T cell-mediated antitumor responses by a helper HER-2/neu peptide linked to the Ii-Key moiety of the invariant chain. Int J Cancer (2007) 0.83
IGF2BP1 expression in human mesenchymal stem cells significantly affects their proliferation and is under the epigenetic control of TET1/2 demethylases. Stem Cells Dev (2014) 0.83
Identification of a novel immunogenic HLA-A*0201-binding epitope of HER-2/neu with potent antitumor properties. J Immunol (2008) 0.83
A novel quantitative flow cytometric method for measuring glucocorticoid receptor (GR) in cell lines: correlation with the biochemical determination of GR. J Immunol Methods (2007) 0.82
AE37 peptide vaccination in prostate cancer: identification of biomarkers in the context of prognosis and prediction. Cancer Immunol Immunother (2014) 0.81
Prostate cancer vaccines: the long road to clinical application. Cancer Immunol Immunother (2015) 0.81
Targeting of tumor cells by lymphocytes engineered to express chimeric receptor genes. Cancer Immunol Immunother (2004) 0.80
Immune classification of colorectal cancer patients: impressive but how complete? Expert Opin Biol Ther (2013) 0.79
A primer on cancer immunology and immunotherapy. Cancer Immunol Immunother (2004) 0.79
Beneficial effect of short-term exposure of human NK cells to IL15/IL12 and IL15/IL18 on cell apoptosis and function. Cell Immunol (2005) 0.79
Generation of human tumor-specific CTLs in HLA-A2.1-transgenic mice using unfractionated peptides from eluates of human primary breast and ovarian tumors. Cancer Immunol Immunother (2004) 0.78
Natural CD8+ T-cell responses against MHC class I epitopes of the HER-2/ neu oncoprotein in patients with epithelial tumors. Cancer Immunol Immunother (2003) 0.78
Therapeutic cancer vaccines: a long and winding road to success. Expert Rev Vaccines (2014) 0.78
Clinical grade expansion of human bone marrow mesenchymal stem cells. Methods Mol Biol (2007) 0.78
A HER-2/neu peptide admixed with PLA microspheres induces a Th1-biased immune response in mice. Biochim Biophys Acta (2005) 0.77
Immune biomarkers: how well do they serve prognosis in human cancers? Expert Rev Mol Diagn (2014) 0.77
Quantitative fluorescence cytometric measurement of estrogen and progesterone receptors: correlation with the hormone binding assay. Breast Cancer Res Treat (2003) 0.77
Combined treatment with bevacizumab and standard chemotherapy restores abnormal immune parameters in advanced colorectal cancer patients. Invest New Drugs (2010) 0.77
A pilot study in prostate cancer patients treated with the AE37 Ii-key-HER-2/neu polypeptide vaccine suggests that HLA-A*24 and HLA-DRB1*11 alleles may be prognostic and predictive biomarkers for clinical benefit. Cancer Immunol Immunother (2015) 0.77
Invariant chain-peptide fusion vaccine using HER-2/neu. Methods Mol Biol (2014) 0.77
Developing effective cancer vaccines. Eur J Cancer (2011) 0.76
HER-2/neu (657-665) represents an immunogenic epitope of HER-2/neu oncoprotein with potent antitumor properties. Vaccine (2009) 0.76
Identification and characterization of a HER-2/neu epitope as a potential target for cancer immunotherapy. Cancer Immunol Immunother (2009) 0.76
Characterization of a novel cell penetrating peptide derived from Bag-1 protein. Peptides (2006) 0.76
Chemotherapy ± cetuximab modulates peripheral immune responses in metastatic colorectal cancer. Oncology (2013) 0.76
Toxicity profiles of HER2/neu peptide anticancer vaccines: the picture from Phase/I and II clinical trials. Expert Rev Vaccines (2012) 0.76
Serological detection of hepatitis B viral infection by a panel of solid-phase enzyme-linked immunosorbent assays (ELISA). J Pharm Biomed Anal (2004) 0.75
In vitro and in vivo antitumor activity of a mouse CTL hybridoma expressing chimeric receptors bearing the single chain Fv from HER-2/neu- specific antibody and the gamma-chain from Fc(epsilon) RI. Cancer Immunol Immunother (2003) 0.75
Ninth annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), Siena, Italy, October 19-22, 2011: New perspectives in the immunotherapy of cancer. Cancer Immunol Immunother (2012) 0.75
Cancer immunotherapy: perspectives and prospects. Adv Exp Med Biol (2008) 0.75
Efficacy of novel culture environments on the ex vivo expansion kinetics of cord blood progenitor cells. Haematologica (2002) 0.75
Identification of novel breast cancer-associated transcripts by UniGene database mining and gene expression analysis in normal and malignant cells. Genes Chromosomes Cancer (2012) 0.75
A skeletal muscle troponin T specific ELISA based on the use of an antibody against the soluble troponin T (16-31) fragment. J Immunol Methods (2002) 0.75